Celecoxib

Introduction Overview

Generic Name

celecoxib

Brand Name

Celebrex

Dosage Form

oral capsule

Drug Class

Cox-2 inhibitors

Pharmacokinetics

Absorption:
Celecoxib is well absorbed following oral administration with peak plasma concentrations achieved within 2 to 3 hours post-dose. The oral bioavailability is high but may vary with concurrent food intake; however, food does not significantly affect the extent of absorption though it may delay time to peak concentration. The drug demonstrates linear pharmacokinetics over the therapeutic dose range. Studies indicate that celecoxib reaches steady-state plasma levels within five days of consistent dosing. Absorption is not significantly altered by age, gender, or race, though hepatic impairment may modestly affect pharmacokinetics.

Distribution:
Celecoxib is extensively bound to plasma proteins, with approximately 97% binding primarily to albumin. It has a volume of distribution indicative of moderate tissue penetration. Celecoxib crosses certain biological membranes, but its penetration into cerebrospinal fluid is limited. It does distribute into synovial fluid, which corresponds with its clinical efficacy in arthritic conditions. The plasma protein binding remains consistent across therapeutic concentrations, minimizing interactions through displacement.

Metabolism:
The drug is primarily metabolized hepatically via cytochrome P450 isoenzyme CYP2C9 into inactive metabolites. These metabolic transformations involve oxidation and subsequent glucuronide conjugation before elimination. Polymorphisms in CYP2C9 can significantly alter celecoxib metabolism, with poor metabolizers exhibiting increased plasma concentrations and potentially higher risk of adverse effects. Drug interactions that inhibit or induce CYP2C9 activity can also impact celecoxib plasma levels, necessitating dosage adjustments in certain cases.

Elimination:
Celecoxib and its metabolites are predominantly eliminated via the feces (approximately 57%) and to a lesser extent in urine (approximately 27%). The elimination half-life is approximately 11 hours, supporting twice-daily dosing regimens for optimal therapeutic effects. Clearance may be reduced in patients with hepatic dysfunction, requiring cautious use. Renal impairment has minimal impact on celecoxib clearance, and dose adjustments are generally not necessary unless severe renal dysfunction is present. Overall, the pharmacokinetic profile supports effective systemic exposure while minimizing accumulation with regular dosing.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 50 mg, 100 mg, 200 mg, 400 mg
- Oral suspension (Elyxyb): primarily for patients with swallowing difficulties (Exact concentrations per formulation vary)

Dosages for Adults and Adolescents:
- Acute Pain: Initiate with 400 mg orally, followed by 200 mg if needed on the first day; thereafter, 200 mg twice daily as required.
- Dysmenorrhea: Initial 400 mg followed by 200 mg if needed on day one; then 200 mg twice daily.
- Osteoarthritis: 200 mg once daily or 100 mg twice daily.
- Rheumatoid Arthritis: 100 to 200 mg twice daily.
- Familial Adenomatous Polyposis: 400 mg twice daily with food.
- Ankylosing Spondylitis: 200 mg once daily or 100 mg twice daily; if no improvement after 6 weeks, trial of 400 mg daily may be considered.
- Juvenile Rheumatoid Arthritis (≥ 2 years old):
- 10 to ≤25 kg: 50 mg twice daily
- >25 kg: 100 mg twice daily

Specific Patient Populations:
- Pediatric patients ≥2 years with juvenile rheumatoid arthritis have tailored dosing based on weight.
- No specific dosage adjustment for mild to moderate renal impairment; use caution in severe renal impairment.
- Hepatic impairment necessitates careful use; pharmacokinetics may be altered; dose adjustments may be required.
- Elderly patients generally do not require dosage modification but should be monitored for adverse effects due to increased risk.
- Celecoxib capsules can be opened and their contents sprinkled on applesauce for patients unable to swallow capsules, with the mixture refrigerated if used within 6 hours.

Mechanism Of Action

Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme responsible for the biosynthesis of prostaglandins involved in inflammation and pain. Unlike nonselective NSAIDs, which inhibit both COX-1 and COX-2 enzymes, celecoxib preferentially targets COX-2, which is inducible and highly expressed at sites of inflammation.

At the molecular level, celecoxib binds reversibly to the active site of the COX-2 enzyme, blocking the conversion of arachidonic acid to prostaglandin H2, a precursor of pro-inflammatory prostanoids such as prostaglandin E2. This selective inhibition reduces the production of inflammatory mediators, thereby diminishing inflammation, pain, and fever without significantly affecting the COX-1 mediated protective functions in the gastrointestinal tract.

Through this selective inhibition, celecoxib modulates cellular pathways that lead to decreased vasodilation, edema, and leukocyte infiltration, which are hallmarks of the inflammatory response. Additionally, by preserving COX-1 activity, celecoxib maintains platelet function and gastrointestinal mucosal integrity better than traditional NSAIDs, potentially reducing the risk of gastrointestinal bleeding.

Clinical investigations demonstrate that celecoxib’s mechanism results in effective management of symptoms in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, and familial adenomatous polyposis. Comparative studies show celecoxib has a more favorable gastrointestinal safety profile compared to nonselective NSAIDs, attributed to its selective COX-2 inhibition, although cardiovascular risk remains a concern requiring consideration during therapy.

Pharmacological Actions

Selective inhibition of cyclooxygenase-2 (COX-2) enzyme activity.
Reduction of prostaglandin synthesis leading to anti-inflammatory effects.
Analgesic action through decreased sensitization of nociceptors to inflammatory mediators.
Antipyretic effects resulting from suppression of prostaglandin-mediated hypothalamic temperature regulation.
Sparing of cyclooxygenase-1 (COX-1) enzyme activity, protecting gastrointestinal mucosa.
Reduction in inflammatory cell migration and edema formation at sites of tissue injury.
Potential modulation of angiogenesis and tumor growth in familial adenomatous polyposis.
Improvement of joint function and mobility in arthritic conditions.
Minimal effect on platelet aggregation compared to nonselective NSAIDs due to COX-1 sparing.
Pharmacodynamic effects consistent with symptomatic relief of various musculoskeletal and inflammatory conditions.

Therapeutic Or Clinical Uses

Management of osteoarthritis symptoms including joint pain and inflammation.
Treatment of rheumatoid arthritis and reduction of associated joint swelling and stiffness.
Treatment of ankylosing spondylitis to improve spinal mobility and reduce inflammation.
Management of acute pain including postoperative pain and other pain syndromes.
Treatment of primary dysmenorrhea by alleviating menstrual cramps and associated discomfort.
Therapy of juvenile rheumatoid arthritis in pediatric patients aged 2 years and older.
Reduction of polyp formation in patients with familial adenomatous polyposis as adjunct therapy.
Alternative to nonselective NSAIDs in patients at elevated risk for gastrointestinal adverse effects.
Symptomatic relief of other inflammatory conditions where NSAID therapy is indicated per physician discretion.
Short-term pain relief in musculoskeletal injuries and soft tissue disorders.

Side Or Adverse Effects

Gastrointestinal discomfort including abdominal pain, dyspepsia, and heartburn.
Gastrointestinal bleeding, ulceration, and perforation which may be fatal, especially in elderly patients.
Edema and peripheral swelling, possibly related to sodium and water retention.
Dizziness and headache occurring in some patients.
Upper respiratory tract symptoms such as nasal congestion, sore throat, and sinusitis.
Nausea and vomiting, with occasional reports of diarrhea or constipation.
Hypertension or exacerbation of pre-existing hypertension.
Skin reactions including rash, pruritus, and rare severe hypersensitivity such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
Potential hepatotoxicity manifested by elevated liver enzymes, jaundice, and rarely liver failure.
Renal impairment or acute kidney injury, particularly in patients with predisposing conditions.
Cardiovascular events including increased risk of myocardial infarction and stroke.
Anemia and hematologic abnormalities such as thrombocytopenia.
Allergic reactions, including urticaria, angioedema, and anaphylaxis in sensitive individuals.
Increased risk of serious skin reactions leading to hospitalization or discontinuation.
Rare reports of aseptic meningitis and other neurological adverse events.

Precautions

Use with caution in patients with history of gastrointestinal ulcers or bleeding.
Monitor blood pressure regularly due to potential hypertensive effects.
Avoid use in patients with known sulfonamide allergy due to molecular structure related to sulfonamides.
Consider renal and hepatic function prior to initiation and monitor periodically.
Avoid concomitant use with other NSAIDs or aspirin unless prescribed by a physician.
Use the lowest effective dose for the shortest duration consistent with treatment goals.
Monitor for signs of cardiovascular events, especially in patients with risk factors such as hypertension or atherosclerosis.
Avoid use in late pregnancy (after 20 weeks gestation) due to risk of fetal cardiovascular and renal complications.
Assess for hypersensitivity reactions in patients with asthma or aspirin-induced respiratory reactions.
Patients should avoid alcohol to minimize risk of gastrointestinal bleeding.
Regular liver function testing recommended during prolonged therapy.
Dose adjustment and careful monitoring in elderly patients due to increased risks of adverse effects.
Educate patients about signs of bleeding, rash, or hypersensitivity and instruct to seek immediate medical attention if symptoms develop.
Avoid use immediately before or after coronary artery bypass graft surgery due to elevated risk of adverse cardiovascular events.
Cautious use advised in patients with fluid retention or chronic heart failure.

Warnings

Increased risk of serious cardiovascular thrombotic events including myocardial infarction and stroke, which can be fatal.
Risk of fatal gastrointestinal bleeding, ulceration, and perforation may occur at any time during therapy without warning symptoms.
Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Potential for severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis requiring immediate discontinuation.
Use in patients with sulfa allergy requires careful consideration due to chemical relatedness to sulfonamides.
Not recommended during the third trimester of pregnancy due to risk of premature closure of the fetal ductus arteriosus.
May cause renal toxicity including acute renal failure especially in patients with underlying renal impairment.
Use with caution in patients with hypertension, congestive heart failure, or risk factors for cardiovascular disease.
Increased monitoring required in elderly patients who are at greater risk for adverse events.
Avoid concomitant use with other NSAIDs due to additive risk of adverse gastrointestinal and cardiovascular effects.
Discontinue if signs of liver toxicity such as jaundice or unexplained malaise occur.
May cause anemia due to possible gastrointestinal blood loss.
Can exacerbate asthma or allergic-type reactions in sensitive individuals.
Serious skin reactions may present initially with fever, sore throat, and facial swelling.
Patients should be monitored closely for any signs of bleeding, cardiovascular or dermatologic adverse effects during therapy.

Contraindication

Known hypersensitivity to celecoxib or any component of the formulation.
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
Patients with significant active gastrointestinal bleeding or ulceration.
Use during the perioperative period of coronary artery bypass graft (CABG) surgery.
Severe hepatic impairment or active liver disease.
Patients with established advanced renal disease or severe renal impairment.
Known hypersensitivity to sulfonamide derivatives given chemical structure similarity.
Pregnancy in the last trimester (after 30 weeks gestation).
History of severe allergic reactions, including anaphylaxis to NSAIDs.
Patients with bleeding disorders or coagulopathy without appropriate medical supervision.
Concomitant use with ketorolac or pentoxifylline due to increased bleeding risk.
Use in patients with history of aspirin-exacerbated respiratory disease.
Known hypersensitivity reactions to any COX-2 inhibitors.
Individuals with active inflammatory bowel disease flare-ups.
Concomitant treatment with other drugs contraindicated with NSAIDs based on interaction profile.

Drug Interactions

Concomitant use with anticoagulants (e.g., warfarin) increases bleeding risk.
Interaction with other NSAIDs or aspirin may heighten gastrointestinal toxicity.
CYP2C9 inhibitors (e.g., fluconazole) can increase celecoxib plasma levels, requiring dose adjustment.
CYP2C9 inducers (e.g., rifampin) may reduce celecoxib effectiveness by increasing metabolism.
Increased risk of lithium toxicity when used with celecoxib due to reduced renal clearance of lithium.
Concomitant use with ACE inhibitors or diuretics may reduce antihypertensive effects and increase renal toxicity.
May increase serum digoxin concentration requiring monitoring of digoxin levels.
Coadministration with methotrexate may increase methotrexate toxicity through reduced clearance.
Potential interaction with selective serotonin reuptake inhibitors (SSRIs) and other antiplatelet agents increasing bleeding risk.
Interaction with corticosteroids may further increase the risk of gastrointestinal ulceration or bleeding.
May interfere with antihypertensive therapy including beta-blockers.
Concomitant use with cyclosporine may increase nephrotoxic potential.
Herbal supplements like ginkgo biloba or garlic may increase bleeding risk when taken with celecoxib.
Avoid or closely monitor interactions with drugs that impair renal function or fluid retention.
Potential interaction with aspirin affecting platelet function, but celecoxib has minimal impact on platelet aggregation itself.

Preparations Of The Drug

Oral capsules available in strengths of 50 mg, 100 mg, 200 mg, and 400 mg.
Oral suspension formulation (Elyxyb) for patients with difficulty swallowing capsules.
Capsules contain celecoxib as the active ingredient with excipients formulated to enhance bioavailability.
Storage at controlled room temperature away from excessive moisture and heat.
Capsules can be opened and the contents mixed with applesauce for patients unable to swallow whole capsules.
Available in both brand (Celebrex) and generic formulations with equivalent efficacy.
Parenteral forms are not available; only oral administration is approved.
Packaging includes child-resistant containers to prevent accidental ingestion by children.
Formulations designed with COX-2 selectivity to minimize gastrointestinal adverse effects compared to traditional NSAIDs.
Manufactured according to FDA-approved standards ensuring purity and stability.
Available through prescription only with detailed patient medication guides to inform about usage and risks.
Formulated without aspirin or other NSAIDs to avoid additive toxicity.
Each capsule provides calibrated dosing to accommodate titration based on clinical response.
Wide availability in many countries with multiple generic brands ensuring accessibility.